Moreover, we identified SHP2 phase separation as a core mechanism of complex I and III dysregulation, which suggests that targeting SHP2 phase separation can serve as a potential therapeutic target in the treatment of SHP2-associated cancers. Here, PTPN11 is linked to cancer.